Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020;25(6):895-930.
doi: 10.1007/s12257-020-0049-y. Epub 2021 Jan 7.

Artificial Intelligence in Drug Discovery: A Comprehensive Review of Data-driven and Machine Learning Approaches

Hyunho Kim  1 , Eunyoung Kim  1 , Ingoo Lee  1 , Bongsung Bae  1 , Minsu Park  1 , Hojung Nam  1
Affiliations
Review

Artificial Intelligence in Drug Discovery: A Comprehensive Review of Data-driven and Machine Learning Approaches

Hyunho Kim et al. Biotechnol Bioprocess Eng. 2020.

Abstract

As expenditure on drug development increases exponentially, the overall drug discovery process requires a sustainable revolution. Since artificial intelligence (AI) is leading the fourth industrial revolution, AI can be considered as a viable solution for unstable drug research and development. Generally, AI is applied to fields with sufficient data such as computer vision and natural language processing, but there are many efforts to revolutionize the existing drug discovery process by applying AI. This review provides a comprehensive, organized summary of the recent research trends in AI-guided drug discovery process including target identification, hit identification, ADMET prediction, lead optimization, and drug repositioning. The main data sources in each field are also summarized in this review. In addition, an in-depth analysis of the remaining challenges and limitations will be provided, and proposals for promising future directions in each of the aforementioned areas.

Keywords: artificial intelligence; data-driven; drug discovery; machine learning.

PubMed Disclaimer

References

    1. J. A D, Grabowski H G, Hansen R W. Innovation in the pharmaceutical industry: New estimates of R&D costs. J. Health Econ. 2016;47:20–33. doi: 10.1016/j.jhealeco.2016.01.012. - DOI - PubMed
    1. S. M P, Mytelka D S, Dunwiddie C T, Persinger C C, Munos B H, Lindborg S R, Schacht A L. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 2010;9:203–214. doi: 10.1038/nrd3078. - DOI - PubMed
    1. H v d W, Gifford E. ADMET in silico modelling: towards prediction paradise? Nat. Rev. Drug Discov. 2003;2:192–204. doi: 10.1038/nrd1032. - DOI - PubMed
    1. K. K M, Pichika M R. Artificial intelligence in drug development: present status and future prospects. Drug Discov. Today. 2019;24:773–780. doi: 10.1016/j.drudis.2018.11.014. - DOI - PubMed
    1. X Y, Wang Y, Byrne R, Schneider G, Yang S. Concepts of artificial intelligence for computer-assisted drug discovery. Chem. Rev. 2019;119:10520–10594. doi: 10.1021/acs.chemrev.8b00728. - DOI - PubMed

LinkOut - more resources